Skye Bioscience, Inc. Common Stock
SKYESkye Bioscience, Inc. (SKYE) is a biotechnology company focused on developing cannabinoid-based pharmaceutical products. The company aims to leverage its proprietary formulations and delivery technologies to create targeted therapies for various medical conditions, including glaucoma and other ophthalmic diseases. Skye Bioscience focuses on advancing innovative treatments that utilize cannabinoids to address unmet medical needs.
Company News
Rosen Law Firm alerts Skye Bioscience investors about a securities class action lawsuit alleging false statements about the company's drug nimacimab and its clinical prospects during the period of November 4, 2024 to October 3, 2025.
5AM Venture Management sold its entire 189,593 share stake in Viking Therapeutics, representing a $5.02 million position change. The sale appears to be a portfolio rebalancing rather than a lack of confidence in the company's potential.
Skye Bioscience is developing a weight loss drug, nimacimab, that could be an alternative to GLP-1 agonists like those sold by Eli Lilly. Nimacimab aims to reduce the gastrointestinal side effects common with GLP-1 drugs, but may be less effective in inducing weight loss on its own.
The article discusses three micro-cap stocks with significant potential and risk: Rent the Runway (RENT), 374Water (SCWO), and Skye Bioscience (SKYE). These companies operate in the clothing rental, wastewater treatment, and pharmaceutical industries, respectively, and have the potential for massive growth but also carry high risks.
